GRI
GRI Bio Inc

6,553
Loading...
Loading...
News
all
press releases
Barclays lifts Kojamo, I-RES ratings; cuts Grainger on low yield
investing.com·3mo ago
News Placeholder
More News
News Placeholder
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) with interim data expected H1 2024 and topline data expected H2 2024...
Globe Newswire·1y ago
News Placeholder
GRI Bio sees cash runway into 3Q24
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
GRI Bio reports 2023 EPS ($28.25) vs. ($24.95) last year
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
Live webcast on Wednesday, April 3rd at 10:10 AM ET LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ( GRI Bio or the Company ), a biotechnology company advancing...
Globe Newswire·1y ago
News Placeholder
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
Company advancing an innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases Ongoing efforts to build a robust global patent estate for a...
Globe Newswire·1y ago
News Placeholder
GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
MHRA authorization expands ongoing U.S. Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis ( IPF ) with interim data expected H1 2024 and...
Globe Newswire·2y ago
News Placeholder
Short Interest in GRI Bio, Inc. (NASDAQ:GRI) Declines By 64.7%
GRI Bio, Inc. (NASDAQ:GRI Get Free Report) was the recipient of a significant drop in short interest in February. As of February 15th, there was short interest totalling 18,600 shares, a...
Zolmax·2y ago
News Placeholder
GRI Bio (NASDAQ:GRI) versus BioMarin Pharmaceutical (NASDAQ:BMRN) Head to Head Comparison
GRI Bio (NASDAQ:GRI Get Free Report) and BioMarin Pharmaceutical (NASDAQ:BMRN Get Free Report) are both medical companies, but which is the better business? We will compare the two...
Zolmax·2y ago
News Placeholder
GRI Bio prices 5M shares at $1.10 in public offering
GRI Bio prices 5M shares at $1.10 in public offering...
SeekingAlpha.com: All News·2y ago

Latest GRI News

View

Advertisement. Remove ads.

Advertisement. Remove ads.